Chrysalis Biotechnology

Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Shyam Ramakrishnan

Darrell H Carney

Screening methods to identify candidate therapeutic agents using a newly identified human caspases-1-like protease.

Regulation of human caspase-1-like protease

Reagents which regulate human transketolase-like enzyme and reagents which bind to human transketolase-like enzyme gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, anemia, and end-stage renal disease, including sensory periphery neuropathy associated with uremia.

Regulation of human transketolase-like enzyme

These compositions are new synthetic peptides and antibodies which are potent chemotactic agents for human neutrophils, and methods for their use. The specificity of these peptides is amino acid sequence specific for binding to a heretofore unidentified receptor on the surface of neutrophils. Neutrophil response to this peptide is specific, since monocytes and fibroblasts do not show any expression of this receptor. Antibodies against these peptides block the chemotactic response. Such antibodies are useful to modulate neutrophil recruitment to a wound site for enhancing or inhibiting inflammation and early effects of wound healing.

Growing community of inventors

Brighton, MA, United States of America

Shyam Ramakrishnan